KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Retained Earnings (2020 - 2025)

AbCellera Biologics (ABCL) has disclosed Retained Earnings for 6 consecutive years, with -$20.5 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Retained Earnings fell 1566.96% year-over-year to -$20.5 million, compared with a TTM value of -$20.5 million through Sep 2025, down 1566.96%, and an annual FY2024 reading of $116.9 million, down 58.21% over the prior year.
  • Retained Earnings was -$20.5 million for Q3 2025 at AbCellera Biologics, down from -$2.7 million in the prior quarter.
  • Across five years, Retained Earnings topped out at $456.1 million in Q3 2022 and bottomed at -$20.5 million in Q3 2025.
  • Average Retained Earnings over 5 years is $100.1 million, with a median of $576000.0 recorded in 2022.
  • The sharpest move saw Retained Earnings soared 70719.57% in 2022, then crashed 1566.96% in 2025.
  • Year by year, Retained Earnings stood at $280000.0 in 2021, then tumbled by 596.79% to -$1.4 million in 2022, then soared by 20214.09% to $279.8 million in 2023, then tumbled by 58.21% to $116.9 million in 2024, then plummeted by 117.56% to -$20.5 million in 2025.
  • Business Quant data shows Retained Earnings for ABCL at -$20.5 million in Q3 2025, -$2.7 million in Q2 2025, and -$7.0 million in Q1 2025.